Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future

Glucagon-like peptide-1 (GLP-1)–based therapy improves glycaemic control through multiple mechanisms, with a low risk of hypoglycaemia and the additional benefit of clinically relevant weight loss. Since Starling and Bayliss first proposed the existence of intestinal secretions that stimulate the pa...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Indian J Endocrinol Metab
Prif Awduron: Kalra, Sanjay, Baruah, Manash P., Sahay, Rakesh K., Unnikrishnan, Ambika Gopalakrishnan, Uppal, Shweta, Adetunji, Omolara
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Medknow Publications & Media Pvt Ltd 2016
Pynciau:
Review Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4792029/
https://ncbi.nlm.nih.gov/pubmed/27042424
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2230-8210.176351
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg